Retatrutide, developed by Soma Pharmaceuticals , is gaining increasing attention as a novel therapy for metabolic control . This innovative drug merges the activity of a GLP-1 receptor activator and a GIP receptor agonist , designed to not only promote reduced body fat but also improve associated